88426-33-9 | Buparvaquone

Packsize	Purity	Availability	Price	Discounted Price
100mg	95%	in stock	$20.00	$14.00
250mg	95%	in stock	$26.00	$18.00
1g	95%	in stock	$50.00	$35.00
5g	95%	in stock	$163.00	$114.00

Description

• Catalog Number: AC05602
• Chemical Name: Buparvaquone
• CAS Number: 88426-33-9
• Molecular Formula: C21H26O3
• Molecular Weight: 326.4293
• MDL Number: MFCD01712789
• SMILES: OC1=C(CC2CCC(CC2)C(C)(C)C)C(=O)c2c(C1=O)cccc2

Computed Properties

• Complexity: 544
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 24
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 5.3

Literature

• Drug delivery systems for the topical treatment of cutaneous leishmaniasis.

  Expert opinion on drug delivery 20120901

• Point mutations in the Theileria annulata cytochrome b gene is associated with buparvaquone treatment failure.

  Veterinary parasitology 20120706

• Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.

  Experimental parasitology 20120301

• Evaluation and structure-activity relationship study of acute toxicity of naphthoquinones to Photobacterium phosphoreum, Photobacterium T3B.

  Bulletin of environmental contamination and toxicology 20100801

• In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone.

  Drug development and industrial pharmacy 20100601

• Cytoplasmic sequestration of p53 promotes survival in leukocytes transformed by Theileria.

  Oncogene 20100527

• In vivo evidence for the resistance of Theileria annulata to buparvaquone.

  Veterinary parasitology 20100511

• The protozoan parasite Theileria annulata alters the differentiation state of the infected macrophage and suppresses musculoaponeurotic fibrosarcoma oncogene (MAF) transcription factors.

  International journal for parasitology 20090801

• Optimization and validation of RP-HPLC-UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: application to pharmacokinetic study.

  Biomedical chromatography : BMC 20080501

• [Therapeutic efficacy of buparvaquone (buparvon) in cattle with theileriosis].

  Turkiye parazitolojii dergisi 20080101

• In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.

  The Journal of antimicrobial chemotherapy 20071001

• Clinical, haematological and therapeutic studies on tropical theileriosis in water buffaloes (Bubalus bubalis) in Egypt.

  Veterinary parasitology 20070531

• Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies.

  Journal of pharmaceutical and biomedical analysis 20070312

• Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.

  The Journal of pharmacy and pharmacology 20070101

• Clinical efficacy and plasma concentrations of two formulations of buparvaquone in cattle infected with East Coast fever (Theileria parva infection).

  Research in veterinary science 20060801

• Evaluation of buparvaquone (BUTA-Kel KELA, Belgium) as a treatment of East Coast fever in cattle, in the peri-urban of Dar Es Salaam city, Tanzania.

  Veterinary parasitology 20060630

• Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology.

  Journal of drug targeting 20050101

• Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20041001

• Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.

  Bioorganic & medicinal chemistry 20040701

• The effect of dexamethasone and promethazine in combination with buparvaquone in the management of East Coast fever.

  The Onderstepoort journal of veterinary research 20040601

• Cerebral theileriosis in a Holstein calf.

  The Veterinary record 20040424

• Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone.

  Journal of medicinal chemistry 20040101

• In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys.

  The Journal of veterinary medical science 20031101

• Theileria parva-transformed T cells show enhanced resistance to Fas/Fas ligand-induced apoptosis.

  Journal of immunology (Baltimore, Md. : 1950) 20030801

• Apoptosis of Theileria-infected lymphocytes induced upon parasite death involves activation of caspases 9 and 3.

  Biochimie 20030801

• Transition metal complexes of buparvaquone as potent new antimalarial agents. 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against Plasmodium falciparum.

  Journal of inorganic biochemistry 20030701

• Constitutive exclusion of Csk from Hck-positive membrane microdomains permits Src kinase-dependent proliferation of Theileria-transformed B lymphocytes.

  Blood 20030301

• Hijacking of host cell IKK signalosomes by the transforming parasite Theileria.

  Science (New York, N.Y.) 20021101

• Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.

  International journal of pharmaceutics 20020426

• Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone.

  International journal of pharmaceutics 20010219